Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google
ENTITY
SMARTSCORE: 3.2/5
Hutchison China Meditech (HCM LN)
Watchlist
26
Analysis
Health Care
•
Hong Kong
Hutchison China MediTech Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech markets its products globally.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Hutchison China Meditech
•
29 Nov 2019 12:17
•
Issuer-paid
Hutchison China MediTech - Elunate receives China NRDL inclusion
Hutchison China MediTech (HCM) has announced that Elunate (fruquintinib capsules) have been included in China’s National Reimbursement Drug List...
Edison Investment Research
Follow
918 Views
Share
bullish
•
Hutchison China Meditech
•
28 Nov 2019 15:59
•
Issuer-paid
Hutchison China MediTech - Elunate receives China NRDL inclusion
Hutchison China MediTech (HCM) has announced that Elunate (fruquintinib capsules) have been included in China’s National Reimbursement Drug List...
Edison Investment Research
Follow
949 Views
Share
bullish
•
Hutchison China Meditech
•
10 Oct 2019 11:02
•
Issuer-paid
Hutchison China MediTech - Surufatinib NETs solid data at ESMO
Hutchison China MediTech (HCM) presented robust SANET-ep Phase III China data at ESMO 2019 on surufatinib in non-pancreatic neuroendocrine tumors...
Edison Investment Research
Follow
1.3k Views
Share
bullish
•
Hutchison China Meditech
•
09 Oct 2019 13:34
•
Issuer-paid
Hutchison China MediTech - Surufatinib NETs solid data at ESMO
Hutchison China MediTech (HCM) presented robust SANET-ep Phase III China data at ESMO 2019 on surufatinib in non-pancreatic neuroendocrine tumours...
Edison Investment Research
Follow
1.3k Views
Share
bullish
•
Hutchison China Meditech
•
17 Aug 2018 08:05
•
Issuer-paid
Hutchison China MediTech - Establishing a global operational presence
Highlights from Hutchison China MediTech’s (HCM) H118 results relate to the substantial pipeline-related newsflow expected in 2018/19, the recent...
Edison Investment Research
Follow
128 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.1
x